Popular Articles

Genomes Of Parasitic Flatworms Decoded
Two international research teams have determined the complete genetic sequences of two species of parasitic flatworms that cause schistosomiasis, a debilitating condition also known as snail fever. Schistosoma mansoni and Schistosoma japonicum are the first sequenced genomes of any organism in the large group called Lophotrochozoa, which includes other free-living and parasitic flatworms as well as segmented roundworms, such as the earthworm.
generic viagra online
Provectus Pharmaceuticals Initiates New PH-10 Clinical Study For Psoriasis
Provectus Pharmaceuticals, Inc. (OTC BB: PVCT ), a development-stage oncology and dermatology biopharmaceutical company, has initiated a new Phase 2 clinical trial of PH-10 for psoriasis involving daily dosing of patients for 28 days. After reviewing safety and efficacy data from its PH-10 trial for atopic dermatitis, Provectus determined that daily dosing of patients with psoriasis trial would be an appropriate and attractive regimen. The new study supplants an earlier Phase 2 study, using twice weekly dosing for 12 weeks, which was terminated earlier in June.
News of the day
Victorian HIV Test To Help Monitor Sufferers
People living with HIV will benefit from a new test developed by Victoria, Australia scientists that offers a simpler and cheaper way of monitoring the disease in sufferers, Victorian Innovation Minister Gavin Jennings said today.
Medical Devices

Joint Replacement Patients With Diabetes Greatly Benefit From Controlled Glucose

Diabetics undergoing total joint replacement often are at a higher risk of experiencing complications after surgery due to various pre-existing health conditions. According to a new study published in the July 2009 issue of The Journal of Bone and Joint Surgery (JBJS), those complications are less likely to occur when a diabetic patient has glucose levels under control. "We found that controlled glucose levels really do make a difference for the patient," said study co-author Milford Marchant Jr., MD, an orthopaedic surgeon who conducted the study with colleagues of the Adult Reconstruction Section at Duke University Medical Center. The study found that patients with uncontrolled glucose levels were: -- More than 3 times as likely to experience a stroke or death after joint replacement surgery; and -- About twice as likely to experience post-operative bleeding and infection. Dr. Marchant and his colleagues reviewed data from a national healthcare database looking at more than one million patients who had total joint replacement surgery from 1988 to 2005. They compared surgical outcomes in patients with uncontrolled glucose levels to those who had controlled glucose levels and those patients who did not have diabetes. "It did not matter if the patient had Type I or Type II diabetes," explains Dr. Marchant. "Regardless of diabetes type, we found that patients had fewer complications after surgery if their glucose level was controlled before, during and after surgery." Diabetic patients with uncontrolled glucose were more likely to experience surgical complications, infection, blood transfusions and longer hospitals stays. "The factors necessary for diabetic patients to be considered "under control" are different for each individual patient, therefore diabetic patients should have good relationships with their medical doctors," said Dr. Marchant. Study authors say that according to the American Diabetes Association, disease control is determined for each patient based on a series of laboratory blood tests and an assessment of diabetes-related illnesses. Approximately 8 percent of patients undergoing total hip and knee replacement in the United States have diabetes. "It is crucial that patients have glucose levels well managed before, during and after surgery because it reduces the potential of having a complication," notes Dr. Marchant. "This is the responsibility of both the patient and the surgeon, and it should be a priority." Disclosure: The authors did not receive any outside funding or grants in support of their research for or preparation of this work. Neither they nor a member of their immediate families received payments or other benefits or a commitment or agreement to provide such benefits from a commercial entity. Commercial entities (Zimmer and DePuy) paid or directed in any one year, or agreed to pay or direct, benefits in excess of $10,000 to a research fund, foundation, division, center, clinical practice, or other charitable or nonprofit organization with which one or more of the authors, or a member of his or her immediate family, is affiliated or associated. American Academy of Orthopaedic Surgeons


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):